Quick Answer
LIGAND PHARMACEUTICALS INC reported Stockholders Equity of $1.02 billion for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +22.5% in Stockholders Equity from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $49.61 million | Q1 2014: $65.00 million | Q2 2014: $64.17 million | Q3 2014: $44.37 million | Q1 2015: $35.15 million | Q2 2015: $69.05 million | Q3 2015: $266.81 million | Q1 2016: $392.08 million | Q2 2016: $391.92 million | Q3 2016: $338.26 million | Q1 2017: $371.83 million | Q2 2017: $385.12 million | Q3 2017: $403.17 million | Q4 2017: $399.79 million | Q1 2018: $481.10 million | Q2 2018: $619.81 million | Q3 2018: $699.52 million | Q1 2019: $1.08 billion | Q2 2019: $1.04 billion | Q3 2019: $850.58 million | Q1 2020: $661.90 million | Q2 2020: $695.00 million | Q3 2020: $697.82 million | Q1 2021: $745.84 million | Q2 2021: $786.52 million | Q3 2021: $812.07 million | Q1 2022: $793.19 million | Q2 2022: $802.37 million | Q3 2022: $816.30 million | Q1 2023: $646.32 million | Q2 2023: $664.89 million | Q3 2023: $667.90 million | Q1 2024: $806.52 million | Q2 2024: $775.20 million | Q3 2024: $841.18 million | Q1 2025: $795.59 million | Q2 2025: $827.31 million | Q3 2025: $950.17 million.
- Over the full 18 years of available data (2008 to 2025), LIGAND PHARMACEUTICALS INC's Stockholders Equity has grown by 9,913.9%.
- Historical annual values: Fiscal year 2025: $1.02 billion | Fiscal year 2024: $830.44 million | Fiscal year 2023: $700.91 million | Fiscal year 2022: $597.49 million | Fiscal year 2021: $821.16 million | Fiscal year 2020: $709.53 million | Fiscal year 2019: $767.23 million | Fiscal year 2018: $560.91 million | Fiscal year 2017: $399.79 million | Fiscal year 2016: $341.29 million | Fiscal year 2015: $237.28 million | Fiscal year 2014: $26.32 million | Fiscal year 2013: $49.61 million | Fiscal year 2012: $26.49 million | Fiscal year 2011: $8.19 million | Fiscal year 2010: -$4.85 million | Fiscal year 2009: $3.74 million | Fiscal year 2008: -$10.37 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: